Company news

Moderna, Inc. news in 2025

Moderna, Inc.'s news releases, calls and decks from 2025, newest first.

View company

CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate

December 18, 2025

Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 16, 2025

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)

December 14, 2025

Eikon Therapeutics Announces the Election of David W. Meline to its Board of Directors

December 2, 2025

Moderna Secures $1.5 Billion Five-Year Credit Facility from Ares Management

November 19, 2025

Moderna Analyst Day Highlights Pipeline Progress and Business Strategy Updates

November 19, 2025

Moderna Expands U.S. Manufacturing with Onshoring of Drug Product Capabilities

November 18, 2025

Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025

November 17, 2025

Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 5, 2025

Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma

November 2, 2025

Moderna Named a Top Employer by Science for Eleventh Consecutive Year

October 22, 2025

Moderna to Host Investor Event - Analyst Day

October 22, 2025

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

October 21, 2025

Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025

October 18, 2025

Moderna to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

October 15, 2025

Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress

October 11, 2025

Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK

September 23, 2025

Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans

September 22, 2025

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

September 18, 2025

Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans

September 15, 2025

Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism

September 1, 2025

Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2

August 26, 2025

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

August 21, 2025

Moderna to Present at Upcoming Conferences in September 2025

August 20, 2025

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech

July 31, 2025

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates

July 31, 2025

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

July 29, 2025

Moderna Announces Data to be Presented at ESMO Congress 2025

July 27, 2025

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1

July 24, 2025

Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025

July 11, 2025

Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease

July 10, 2025

Former Moderna Chief Development Officer Melanie Ivarsson OBE Joins PhaseV's Scientific Advisory Board

July 1, 2025

Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine

June 29, 2025

Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease

June 11, 2025

Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025

June 10, 2025

Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE

May 30, 2025

Moderna Announces Update on Investigational Pandemic Influenza Program

May 27, 2025

Moderna to Present at Upcoming Conferences in June 2025

May 26, 2025

Moderna Files FDA Application for the LP.8.1 Targeting COVID-19 Vaccine

May 22, 2025

Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19

May 20, 2025

Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025

May 7, 2025

Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates

April 30, 2025

Moderna to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

April 9, 2025

Moderna to Showcase Extensive Infectious Disease Research at ESCMID 2025

April 6, 2025

Moderna Receives Australian Therapeutic Goods Administration Approval for RSV Vaccine for Older Adults

March 30, 2025

Moderna Receives Medicines and Healthcare Products Regulatory Agency Marketing Authorization in the UK for RSV Vaccine

February 27, 2025

Moderna to Present at Upcoming Conferences in March 2025

February 24, 2025

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates

February 13, 2025

Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025

January 28, 2025

Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European Union

January 23, 2025

Older news releases →

Calls in 2025

Decks in 2025